Antihypertensive Drugs

Correct Answer

D — Angiotensin receptor-neprilysin inhibitor

Rationale

Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor. Lisinopril is an angiotensin converting enzyme inhibitor. Aliskiren is a direct renin inhibitor. Spironolactone is a mineralocorticoid receptor antagonist.

Correct Answer

B — Selective mineralocorticoid receptor antagonist

Rationale

Eplerenone is a selective steroidal mineralocorticoid receptor antagonist. Losartan is an angiotensin receptor blocker. Furosemide is a loop diuretic. Finerenone is a non-steroidal mineralocorticoid receptor antagonist, distinct from eplerenone.

Correct Answer

A — Non-dihydropyridine calcium channel blockers

Rationale

Verapamil and diltiazem are non-dihydropyridine calcium channel blockers. Amlodipine and nifedipine are dihydropyridine calcium channel blockers.

Correct Answer

C — Dihydropyridine calcium channel blocker

Rationale

Amlodipine is a dihydropyridine calcium channel blocker. Verapamil is a non-dihydropyridine calcium channel blocker. Metoprolol is a beta-adrenergic receptor antagonist. Spironolactone is a mineralocorticoid receptor antagonist.

Correct Answer

B — Angiotensin receptor blockers

Rationale

Losartan is an angiotensin receptor blocker. Lisinopril is an angiotensin converting enzyme inhibitor. Aliskiren is a direct renin inhibitor. Amlodipine is a calcium channel blocker.

Correct Answer

D — Sodium-glucose cotransporter 2 inhibitors

Rationale

Dapagliflozin and empagliflozin are sodium-glucose cotransporter 2 inhibitors. Liraglutide is a glucagon-like peptide-1 receptor agonist. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor.

Correct Answer

A — Both lisinopril and the sacubitril component inhibit bradykinin degradation through different mechanisms — lisinopril by blocking angiotensin converting enzyme and sacubitril by blocking neprilysin; combining them causes dangerous additive bradykinin accumulation with risk of severe or fatal angioedema

Rationale

Angiotensin converting enzyme and neprilysin are two of the principal enzymes responsible for degrading bradykinin in the body. Lisinopril inhibits angiotensin converting enzyme, preventing one pathway of bradykinin breakdown. Sacubitril (as its active metabolite LBQ657) inhibits neprilysin, preventing a second independent pathway. When both enzymes are inhibited simultaneously, bradykinin cannot be adequately degraded by either route and accumulates to levels that can cause severe bradykinin-mediated angioedema — edema of the lips, tongue, pharynx, or larynx that can be rapidly fatal. This is the mechanistic basis for the absolute prohibition on combining sacubitril-valsartan with any angiotensin converting enzyme inhibitor. The 36-hour washout ensures that the angiotensin converting enzyme inhibitor has been cleared sufficiently before the neprilysin inhibition from sacubitril begins. Angiotensin receptor blockers do not inhibit angiotensin converting enzyme and do not accumulate bradykinin, which is why valsartan (an angiotensin receptor blocker) can be safely included in the sacubitril-valsartan combination.

Correct Answer

C — Non-dihydropyridine calcium channel blockers block cardiac L-type calcium channels with approximately equal potency to their vascular effects, reducing myocardial contractility in an already-compromised ventricle; amlodipine selectively blocks vascular L-type channels with minimal cardiac depression at therapeutic doses

Rationale

The key distinction between the two calcium channel blocker subclasses is tissue selectivity. Dihydropyridines — including amlodipine — have high vascular-to-cardiac selectivity: they bind preferentially to vascular smooth muscle L-type calcium channels, producing potent arteriolar vasodilation with minimal direct effects on cardiac contractility, heart rate, or atrioventricular conduction at therapeutic doses. Non-dihydropyridines — verapamil and diltiazem — have approximately equal affinity for L-type calcium channels in vascular smooth muscle and cardiac myocytes. In cardiac tissue, L-type calcium channel blockade reduces the calcium-dependent excitation-contraction coupling that drives myocardial contraction, producing a negative inotropic effect — reduced contractility. In a patient with heart failure with reduced ejection fraction, cardiac contractility is already severely compromised; adding a drug that further reduces it can precipitate acute decompensation, cardiogenic shock, or death. This is why non-dihydropyridines are absolutely contraindicated in heart failure with reduced ejection fraction, while amlodipine — which does not meaningfully depress cardiac contractility — is safe and useful for additional blood pressure control in these patients.

Correct Answer

B — Initiated within 3 to 14 days of myocardial infarction in patients with ejection fraction at or below 40 percent and either heart failure symptoms or diabetes, already on an angiotensin converting enzyme inhibitor and a beta-blocker — reduces all-cause mortality by 15 percent

Rationale

The EPHESUS trial established the post-myocardial infarction indication for eplerenone with specific and testable eligibility criteria. Patients must meet all of the following: an ejection fraction at or below 40 percent (indicating left ventricular dysfunction after myocardial infarction); the presence of either clinical heart failure symptoms or a diagnosis of diabetes; and they must already be receiving both an angiotensin converting enzyme inhibitor and a beta-adrenergic receptor antagonist as foundational post-myocardial infarction therapy. Eplerenone is then initiated within 3 to 14 days of the infarct — this early window is part of what makes this a time-specific indication. In this population, eplerenone reduced all-cause mortality by 15 percent and the combined endpoint of cardiovascular mortality and morbidity by 13 percent compared with placebo. The mechanism of benefit is aldosterone blockade, which reduces post-infarction myocardial fibrosis, prevents adverse ventricular remodeling, and provides blood pressure reduction as an added property. Serum potassium and renal function must be monitored given the hyperkalemia risk when a mineralocorticoid receptor antagonist is added to a renin-angiotensin-aldosterone system inhibitor.

Correct Answer

D — Angiotensin II activates transforming growth factor beta in atrial tissue, promoting interstitial fibrosis that disrupts atrial electrical conduction; renin-angiotensin-aldosterone system inhibitors suppress this pathway, reducing atrial fibrosis and left atrial enlargement — the structural substrate for atrial fibrillation

Rationale

Hypertension promotes atrial fibrillation through a structural remodeling pathway that is distinct from the blood pressure effect on ventricular load. Chronically elevated angiotensin II acts on atrial fibroblasts to activate transforming growth factor beta signaling, which drives interstitial collagen deposition and atrial fibrosis. This fibrosis disrupts the orderly propagation of atrial electrical impulses by creating areas of slow conduction and conduction block — generating the re-entrant circuits required to sustain atrial fibrillation. Hypertension also causes left ventricular hypertrophy and diastolic dysfunction, which raise left atrial filling pressure, enlarging the left atrium and expanding the fibrotic substrate available for atrial fibrillation maintenance. By blocking the renin-angiotensin-aldosterone system, angiotensin converting enzyme inhibitors and angiotensin receptor blockers reduce angiotensin II-driven transforming growth factor beta activation, slow atrial fibrosis, and promote regression of left atrial enlargement. The LIFE trial demonstrated that losartan-based therapy reduced the incidence of new-onset atrial fibrillation compared with atenolol-based therapy by approximately 33 percent in hypertensive patients with left ventricular hypertrophy, despite equivalent blood pressure control — directly attributing the benefit to renin-angiotensin-aldosterone system inhibition rather than blood pressure reduction alone.

Correct Answer

A — Beta-blocker must be given first to achieve heart rate below 60 beats per minute; a vasodilator is added only after heart rate is controlled — giving a vasodilator first causes reflex tachycardia that increases the rate of aortic pressure rise (dP/dt), propagating the dissection

Rationale

In acute aortic dissection, the primary hemodynamic target is reducing the rate of pressure rise in the aorta (dP/dt) — the force that drives the dissection plane further along the aortic wall. Both high blood pressure and high heart rate increase dP/dt, and each must be reduced urgently. The sequencing rule exists because of the baroreceptor reflex: when a vasodilator is given first, the sudden drop in blood pressure triggers baroreceptor-mediated sympathetic activation, causing reflex tachycardia. A rapid heart rate increases dP/dt, potentially worsening dissection propagation at the very moment blood pressure is falling. By giving a beta-blocker first — intravenous esmolol or labetalol, targeting heart rate below 60 beats per minute — the baroreceptor reflex is blunted, preventing the tachycardic response. Only after heart rate is adequately controlled is a vasodilator added to further reduce blood pressure toward the systolic target of 100 to 120 millimeters of mercury. Intravenous labetalol is particularly useful because it provides both rate and pressure reduction in a single agent through its combined alpha and beta-adrenergic receptor antagonism.

Correct Answer

C — Chronic pressure overload from hypertension causes concentric left ventricular hypertrophy, myocardial fibrosis, and diastolic dysfunction — blood pressure control to below 130/80 millimeters of mercury is the most impactful intervention, and sodium-glucose cotransporter 2 inhibitors now carry Class I or IIa guideline recommendations regardless of diabetes status

Rationale

Heart failure with preserved ejection fraction develops through a specific structural sequence driven predominantly by hypertension. Chronic pressure overload forces the left ventricle to generate higher pressures with each beat, stimulating concentric hypertrophy — the ventricular wall thickens while the chamber volume remains normal or decreases. This concentric hypertrophy produces myocardial fibrosis and stiffness, impairing the ventricle's ability to relax and fill normally during diastole (diastolic dysfunction) while systolic ejection fraction remains preserved. Unlike heart failure with reduced ejection fraction, heart failure with preserved ejection fraction lacks drug classes with proven mortality reduction in large trials — no single class has demonstrated the mortality benefit seen with the four pillars in heart failure with reduced ejection fraction. Effective blood pressure control to below 130/80 millimeters of mercury is the most impactful modifiable intervention because it addresses the primary upstream driver of hypertrophy and fibrosis. Sodium-glucose cotransporter 2 inhibitors have been shown to reduce the composite of cardiovascular death and heart failure hospitalization in heart failure with preserved ejection fraction trials regardless of diabetes status and now carry Class I or IIa recommendations — representing the most important recent advance in this condition's management.

Correct Answer

B — Cardioselective beta-blockers are acceptable when a cardiac indication exists — meta-analyses have not confirmed meaningful worsening of claudication with cardioselective agents, and withholding them denies the patient proven mortality benefit; non-selective agents may worsen claudication and should be avoided when alternatives exist

Rationale

The historical concern that beta-blockers worsen peripheral arterial disease by blocking peripheral vasodilatory beta-2 receptors has been addressed by clinical evidence. Meta-analyses of beta-blocker use in patients with peripheral arterial disease have found no statistically or clinically meaningful worsening of claudication distance with cardioselective beta-1 antagonists — agents such as bisoprolol, nebivolol, and metoprolol succinate. This is consistent with the pharmacological logic: cardioselective agents have substantially less beta-2 receptor activity at therapeutic doses, limiting their effect on peripheral vascular tone. In a patient with peripheral arterial disease who also has heart failure with reduced ejection fraction or has had a myocardial infarction, withholding a proven mortality-reducing drug based on concern for a side effect not demonstrated in clinical evidence would be medically unjustified. Non-selective beta-adrenergic receptor antagonists — including carvedilol, propranolol, and labetalol — have more potential to worsen limb blood flow through beta-2 blockade and should be avoided in peripheral arterial disease when cardioselective alternatives are available, although even non-selective agents do not uniformly worsen claudication.

Correct Answer

D — Uncontrolled hypertension while on anticoagulation markedly increases intracranial hemorrhage risk — cerebral small vessels already damaged by hypertension are prone to rupture when anticoagulated, and reducing systolic blood pressure below 130 millimeters of mercury lowers this risk

Rationale

Anticoagulation for stroke prevention in atrial fibrillation shifts bleeding risk from ischemic stroke toward hemorrhagic complications, including intracranial hemorrhage — the most feared and often fatal bleeding event. Hypertension and anticoagulation interact adversely in the cerebral vasculature: chronic hypertension damages cerebral small vessels (lipohyalinosis, microaneurysm formation, and loss of vascular autoregulation), making them prone to rupture under elevated pressure. When anticoagulants impair clotting at the same sites, small vessel hemorrhages that might otherwise be contained become clinically significant intracranial bleeds. The risk of intracranial hemorrhage on anticoagulation rises substantially with systolic blood pressures above 130 to 140 millimeters of mercury, making blood pressure control a modifiable determinant of anticoagulation safety. A specific systolic target below 130 millimeters of mercury for anticoagulated atrial fibrillation patients is recommended to reduce this risk. Hypertension also contributes to the CHA₂DS₂-VASc score — the clinical risk score that guides anticoagulation initiation — adding one point for the presence of hypertension, reflecting its independent contribution to stroke and cardiovascular event risk in atrial fibrillation.

Correct Answer

C — Sacubitril-valsartan cannot be started until at least 36 hours after the last lisinopril dose — lisinopril and the sacubitril component both prevent bradykinin degradation through different enzymes, and simultaneous blockade risks life-threatening angioedema from additive bradykinin accumulation

Rationale

The 36-hour washout is a mandatory safety requirement before initiating sacubitril-valsartan after any angiotensin converting enzyme inhibitor. Lisinopril inhibits angiotensin converting enzyme, which is responsible for degrading bradykinin. The sacubitril component of sacubitril-valsartan inhibits neprilysin, a separate enzyme that also degrades bradykinin. When both enzymes are blocked simultaneously, bradykinin accumulates to levels that cause severe bradykinin-mediated angioedema — swelling of the face, lips, tongue, and airway that can be life-threatening. With the last lisinopril dose taken Tuesday morning and the 36-hour washout applied, sacubitril-valsartan can be started no earlier than Wednesday evening. This is not about plasma half-life of lisinopril alone — it is about ensuring that angiotensin converting enzyme inhibition has dissipated to a degree that safely permits neprilysin inhibition to be added. The valsartan component does not accumulate bradykinin, which is why angiotensin receptor blockers can be combined with sacubitril without this washout requirement.

Correct Answer

A — Diltiazem is a non-dihydropyridine calcium channel blocker that is absolutely contraindicated in heart failure with reduced ejection fraction — its negative inotropy would further depress his already-compromised contractility; and adding it to metoprolol risks severe additive atrioventricular nodal suppression with bradycardia or heart block

Rationale

Two independent contraindications apply here. First, non-dihydropyridine calcium channel blockers — verapamil and diltiazem — are absolutely contraindicated in heart failure with reduced ejection fraction because their cardiac L-type calcium channel blockade reduces myocardial contractility. In a patient with an ejection fraction of 35 percent, this negative inotropy could precipitate acute decompensation. This prohibition is unconditional regardless of the reason diltiazem is being considered. Second, diltiazem and metoprolol both suppress the sinoatrial node and slow atrioventricular nodal conduction — combining them creates additive nodal suppression that can cause severe bradycardia, complete atrioventricular block, or asystole. When a patient with heart failure with reduced ejection fraction has atrial fibrillation with inadequate rate control despite a maximally tolerated beta-blocker, the appropriate options include digoxin (which provides additional rate control without the negative inotropy of non-dihydropyridine calcium channel blockers) or consideration of rhythm control through cardioversion or ablation.

Correct Answer

D — Eplerenone — he meets all EPHESUS criteria: ejection fraction at or below 40 percent, heart failure symptoms, within 3 to 14 days of myocardial infarction, and already on an angiotensin converting enzyme inhibitor and a beta-blocker with acceptable potassium and renal function

Rationale

This patient precisely satisfies the EPHESUS trial eligibility criteria for post-myocardial infarction eplerenone: ejection fraction at or below 40 percent (his is 35 percent); clinical heart failure symptoms (bilateral crackles and ankle edema); he is within the 3 to 14 day initiation window (day 5); and he is already receiving both an angiotensin converting enzyme inhibitor (lisinopril) and a beta-adrenergic receptor antagonist (carvedilol) — the foundational agents that must be in place before eplerenone is added. His potassium of 4.2 mEq/L is below the contraindication threshold of 5.0 mEq/L, and his creatinine of 1.1 milligrams per deciliter is below the male threshold of 2.5 milligrams per deciliter. Adding eplerenone at this time would be expected to reduce all-cause mortality by 15 percent based on trial data. Diltiazem is absolutely contraindicated in heart failure with reduced ejection fraction. The sacubitril-valsartan 36-hour washout from lisinopril cannot be waived in any setting — the angioedema risk is unconditional.

Correct Answer

B — Add amlodipine — as a long-acting dihydropyridine, it dilates coronary and peripheral arterioles without cardiac nodal depression; non-dihydropyridine calcium channel blockers must be avoided because combining them with a beta-blocker risks severe additive atrioventricular nodal suppression

Rationale

In a patient with stable coronary artery disease on a beta-blocker requiring additional anti-ischemic and antihypertensive benefit, amlodipine is the correct choice. As a dihydropyridine calcium channel blocker, amlodipine dilates coronary arterioles — relieving vasospasm and reducing myocardial oxygen demand through afterload reduction — and peripheral arterioles, providing blood pressure reduction. It does not affect sinoatrial or atrioventricular nodal conduction, so combining it with metoprolol carries no nodal suppression risk. The CAMELOT trial demonstrated that amlodipine reduced cardiovascular events and slowed atherosclerosis progression in patients with stable coronary artery disease even when blood pressure was near normal, supporting its use in this population. Non-dihydropyridine calcium channel blockers — verapamil and diltiazem — are specifically contraindicated when combined with a beta-blocker in coronary artery disease because both drug classes suppress the sinoatrial and atrioventricular nodes; their combination risks severe bradycardia, high-degree atrioventricular block, or cardiac arrest. Immediate-release nifedipine is also contraindicated — its reflex tachycardia increases myocardial oxygen demand, worsening angina and increasing cardiac risk in coronary artery disease.